[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564927":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":30,"centralContacts":35,"locations":44,"responsibleParty":93,"collaborators":11,"id":95,"slug":96,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":97,"sex":103,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":11,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":11,"overallStatus":47,"whyStopped":11,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},{"fullName":5,"class":6},"Fundacion Dexeus","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Corifollitropin alfa (CFA) 150 mcg + Clomiphene Citrate (CC) 100 mg\u002Fday from D1","EXPERIMENTAL",null,[13,14,15],"Drug: Corifollitropin alfa (CFA) 150 mcg + Clomiphene Citrate (CC) 100 mg\u002Fday from D1","Drug: Clomiphene Citrate (CC) 100 mg\u002Fday from D1","Diagnostic Test: Monitoring cycle",[17,21,25],{"type":18,"name":9,"description":19,"armGroupLabels":20,"otherNames":11},"DRUG","On day 2 or 3 of the menstrual cycle or after 5 days of pill-free interval, a single injection of 150 mcg of CFA (Stimulation Day 1) will be administered.",[9],{"type":18,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"Clomiphene Citrate (CC) 100 mg\u002Fday from D1","On day 2 or 3 of the menstrual cycle or after 5 days of pill-free interval, the patients will start oral administration of Clomiphene Citrate 100\u002Fday continuing up to and including the day of ovulation triggering",[9],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"DIAGNOSTIC_TEST","Monitoring cycle","Scan controls and blood exams will be performed on stimulation days 1, 6, 8, 10 and, according to clinical needs, until trigger day.",[9],[31],{"name":32,"affiliation":33,"role":34},"Nikolaos P Polyzos, MD, PhD","Dexeus Fertility","PRINCIPAL_INVESTIGATOR",[36,40],{"name":32,"role":37,"phone":38,"phoneExt":11,"email":39},"CONTACT","0034932274700","nikpol@dexeus.com",{"name":41,"role":37,"phone":38,"phoneExt":42,"email":43},"Ignacio Rodríguez, MSc","22029","nacrod@dexeus.com",[45,64,76],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Dexeus Mujer Sabadell","RECRUITING","Sabadell","Barcelona","08203","Spain","ES",{"type":54,"coordinates":55},"Point",[56,57],2.10942,41.54329,{"lat":57,"lon":56},[60,62],{"name":61,"role":37,"phone":11,"phoneExt":11,"email":11},"Silvia Grau, MD",{"name":63,"role":34,"phone":11,"phoneExt":11,"email":11},"Silvia Grau",{"facility":65,"status":47,"city":66,"state":49,"zip":67,"country":51,"countryCode":52,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Dexeus Mujer Sant Cugat","Sant Cugat del Vallès","08195",{"type":54,"coordinates":69},[70,71],2.08611,41.47063,{"lat":71,"lon":70},[74,75],{"name":61,"role":37,"phone":11,"phoneExt":11,"email":11},{"name":61,"role":34,"phone":11,"phoneExt":11,"email":11},{"facility":77,"status":78,"city":49,"state":11,"zip":79,"country":51,"countryCode":52,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Departamento de Ginecología Obstetricia y Reproducción. Hospital Universitari Dexeus","NOT_YET_RECRUITING","08037",{"type":54,"coordinates":81},[82,83],2.15899,41.38879,{"lat":83,"lon":82},[86,88,90],{"name":87,"role":37,"phone":38,"phoneExt":42,"email":43},"Ignacio Rodríguez, BsC",{"name":89,"role":34,"phone":11,"phoneExt":11,"email":11},"Nikolaos P Polyzos, MD PhD",{"name":91,"role":92,"phone":11,"phoneExt":11,"email":11},"Valeria Donno, MD","SUB_INVESTIGATOR",{"type":94,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100564927","one-shot-ovarian-stimulation-protocol-one-shot-100564927",false,"NCT06635538","One-shot Ovarian Stimulation Protocol (One-shot)","One-Shot Ovarian Stimulation Protocol: A Pilot Study Investigating the Endocrine Profile","One-shot","Inclusion Criteria:\n\nAge \\\u003C= 40\n\nAMH (Anti-Mullerian Hormone) 1.2-3.5 ng\u002Fml or AFC 7-20\n\nNo family history of hereditary or chromosomal diseases\n\nBody mass index (BMI) 18 to 30 kg\u002Fm2","FEMALE","18 Years","40 Years",{"count":107,"type":108},20,"ESTIMATED","INTERVENTIONAL",[111],"NA","The current prospective observational pilot study aims to evaluate the endocrine profile of a single-injection protocol (single CFA + daily oral administration of CC).",[114],"Infertility, Female","2025-02-25",{"date":117,"type":118},"2025-02-26","ACTUAL",{"date":120,"type":118},"2024-10-31",{"date":122,"type":108},"2025-04",{"name":124,"class":6},"Fundación Santiago Dexeus Font",3]